Bicara Therapeutics
Developing a bifunctional antibody program for head and neck and other solid tumors.
$23.43
After-hours close+0.02 (+0.06%)
At close$23.42(−5.70%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 112.11%Insiders 8.12%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 65.70M · Float 36.30M · 55.3% free float
Institutions13F, as of Jun 30, 2026
182 holders · 73.66M shares · 42 new positions · 111 increased · 40 reduced · 12 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 7.26M | 11.04% | 0 | Aug 14, 2026 |
| T. Rowe Price Investment Management, Inc. | 6.34M | 9.65% | −267.3K | Aug 14, 2026 |
| Siren, L.L.C. | 5.60M | 8.53% | −200.0K | Aug 13, 2026 |
| Vestal Point Capital, LP | 5.25M | 7.99% | −175.0K | Aug 14, 2026 |
| Deep Track Capital, LP | 4.10M | 6.24% | +37.5K | Aug 14, 2026 |
| BlackRock, Inc. | 3.85M | 5.86% | +1.00M | Aug 7, 2026 |
| Jupiter Topco LLC | 3.17M | 4.83% | +3.17Mnew | Aug 14, 2026 |
| Red Tree Management, LLC | 3.16M | 4.81% | −7.0K | Jul 22, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Peter Kolchinskyincl. Rajeev Shah, RA Capital Management, L.P. +1 more | 11.50% | 7.28M | 13D | Mar 2, 2026 ↗ |
| T. Rowe Price Investment Management, Inc. | 10.10% | 6.61M | 13G | Apr 8, 2026 ↗ |
| Vestal Point Capital, LP | 8.30% | 5.43M | 13G | May 15, 2026 ↗ |
| Deep Track Capital, LP | 6.21% | 4.06M | 13G | May 15, 2026 ↗ |
| Red Tree Venture Fund, L.P.incl. Heath Lukatch, Red Tree GP, LLC | 5.80% | 3.17M | 13G | Sep 26, 2024 ↗ |
| 13Gincl. Raymond Debbane, Ulys, L.L.C. +6 more | 5.70% | 3.07M | 13G | Sep 26, 2024 ↗ |
| TPG GP A, LLCincl. Jon Winkelried, James G. Coulter +1 more | 5.50% | 3.01M | 13D | Sep 18, 2024 ↗ |
| BlackRock, Inc. | 5.40% | 3.54M | 13G | Jul 27, 2026 ↗ |
| Janus Henderson Group PLC | 5.10% | 3.34M | 13G | May 15, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | director, 10 percent owner: | 4.60M | 7.01% | Mar 2, 2026 |
| Claire Mazumdar | director, officer: Chief Executive Officer | 362.2K | 0.55% | Aug 12, 2026 |
| Ryan Cohlhepp | director, officer: President and COO | 181.6K | 0.28% | Aug 12, 2026 |
| Ivan Hyep | officer: Chief Financial Officer | 129.9K | 0.20% | Aug 12, 2026 |
| David Raben | officer: Chief Medical Officer | 55.3K | 0.08% | Apr 28, 2026 |
3 ten-percent owners hold 3.90M shares by Form 4, outside the officers-and-directors figure above · 5 people have not refiled in the last 18 months (426.9K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 10, 2026 | Ryan Cohlheppdirector, officer: President and COO | Sale | 18,750 | $27.98 | 181,641 |
| Aug 10, 2026 | Claire Mazumdardirector, officer: Chief Executive Officer | Sale | 10,000 | $27.98 | 362,152 |
| Aug 10, 2026 | Ivan Hyepofficer: Chief Financial Officer | Sale | 12,500 | $27.97 | 129,855 |
| Jul 10, 2026 | Claire Mazumdardirector, officer: Chief Executive Officer | Sale · 2 lots | 10,000 | $28.42 | 362,152 |
| Jul 8, 2026 | Ivan Hyepofficer: Chief Financial Officer | Sale · 3 lots | 28,000 | $28.85 | 129,855 |
| Jul 9, 2026 | Ryan Cohlheppdirector, officer: President and COO | Sale | 536 | $29.00 | 181,641 |
| Jul 8, 2026 | Ryan Cohlheppdirector, officer: President and COO | Sale · 3 lots | 28,214 | $28.98 | 182,177 |
| May 21, 2026 | Ivan Hyepofficer: Chief Financial Officer | Sale | 9,200 | $20.42 | 145,355 |
| May 18, 2026 | Claire Mazumdardirector, officer: Chief Executive Officer | Sale · 2 lots | 15,000 | $20.04 | 362,152 |
| May 15, 2026 | Ryan Cohlheppdirector, officer: President and COO | Sale · 2 lots | 12,500 | $20.29 | 191,641 |
CongressHouse and Senate disclosures
Not reported.